Literature DB >> 16516154

Suppression of apolipoprotein M expression and secretion in alloxan-diabetic mouse: Partial reversal by insulin.

Ning Xu1, Peter Nilsson-Ehle, Bo Ahrén.   

Abstract

We previously reported that apolipoprotein M (apoM) expression is reduced in ob/ob mice. Whether such a reduction is specific for this model or is a more general phenomenon in diabetes models is not known. In the present study, we therefore investigated apoM expression and secretion in NMRI mice rendered diabetes through administration of alloxan (120 mg/kg). Plasma glucose levels were markedly increased and plasma insulin levels markedly reduced at 3 days after alloxan. At the same time, that plasma apoM concentrations were decreased by 70%, apoM mRNA levels in liver was decreased by 40%, and apoM mRNA in kidney was decreased by 20% in alloxan-treated mice compared to saline-injected controls. Furthermore we found also that daily sc administration of insulin (5 IU/kg per day) increased plasma apoM levels, and apoM mRNA levels in liver and kidney. We therefore conclude that apoM is reduced in this diabetes model and that exogenous insulin administrations partially reverses the abnormal apoM expression. Based on these results, we suggest that insulin regulates apoM synthesis in vivo and, therefore, that the reduction of apoM expression is a general phenomenon in diabetes models.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16516154     DOI: 10.1016/j.bbrc.2006.02.022

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

1.  TGF-β Down-regulates Apolipoprotein M Expression through the TAK-1-JNK-c-Jun Pathway in HepG2 Cells.

Authors:  Kun Ren; Zhong-Cheng Mo; Xing Liu; Zhen-Li Tang; Yue Jiang; Xiao-Shan Peng; Qing-Hai Zhang; Jin-Feng Shi; Guang-Hui Yi
Journal:  Lipids       Date:  2016-12-30       Impact factor: 1.880

2.  Regulation of human apolipoprotein m gene expression by orphan and ligand-dependent nuclear receptors.

Authors:  Ioanna Mosialou; Vassilis I Zannis; Dimitris Kardassis
Journal:  J Biol Chem       Date:  2010-07-26       Impact factor: 5.157

3.  Identification of T1D susceptibility genes within the MHC region by combining protein interaction networks and SNP genotyping data.

Authors:  C Brorsson; N T Hansen; K Lage; R Bergholdt; S Brunak; F Pociot
Journal:  Diabetes Obes Metab       Date:  2009-02       Impact factor: 6.577

4.  Expression and localization of apolipoprotein M in human colorectal tissues.

Authors:  Guanghua Luo; Xiaoying Zhang; Qinfeng Mu; Lujun Chen; Lu Zheng; Jiang Wei; Maria Berggren-Söderlund; Peter Nilsson-Ehle; Ning Xu
Journal:  Lipids Health Dis       Date:  2010-09-16       Impact factor: 3.876

5.  Evaluation of Apolipoprotein M Serum Concentration as a Biomarker of HNF-1alpha MODY.

Authors:  Jan Skupien; Grzegorz Kepka; Sylwia Gorczynska-Kosiorz; Anna Gebska; Tomasz Klupa; Krzysztof Wanic; Natalia Nowak; Maciej Borowiec; Jacek Sieradzki; Maciej T Malecki
Journal:  Rev Diabet Stud       Date:  2008-02-10

Review 6.  Druggable Sphingolipid Pathways: Experimental Models and Clinical Opportunities.

Authors:  Victoria A Blaho
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

7.  Hyperglycemia-induced downregulation of apolipoprotein M expression is not via the hexosamine pathway.

Authors:  Bo Jiang; Xiaoying Zhang; Dongmei Di; Guanghua Luo; Yuanping Shi; Jun Zhang; Maria Berggren-Söderlund; Peter Nilsson-Ehle; Ning Xu
Journal:  Lipids Health Dis       Date:  2015-09-16       Impact factor: 3.876

8.  Intralipid decreases apolipoprotein M levels and insulin sensitivity in rats.

Authors:  Lu Zheng; Yuehua Feng; Yuanping Shi; Jun Zhang; Qinfeng Mu; Li Qin; Maria Berggren-Söderlund; Peter Nilsson-Ehle; Xiaoying Zhang; Guanghua Luo; Ning Xu
Journal:  PLoS One       Date:  2014-08-21       Impact factor: 3.240

9.  Modulation of sphingosine-1-phosphate and apolipoprotein M levels in the plasma, liver and kidneys in streptozotocin-induced diabetic mice.

Authors:  Takahiro Nojiri; Makoto Kurano; Yasunori Tokuhara; Shigeo Ohkubo; Masumi Hara; Hitoshi Ikeda; Kazuhisa Tsukamoto; Yutaka Yatomi
Journal:  J Diabetes Investig       Date:  2014-04-21       Impact factor: 4.232

Review 10.  Apolipoprotein M-A Marker or an Active Player in Type II Diabetes?

Authors:  Christina Christoffersen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-21       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.